Consideration of Evidence on Antiemetic Drugs for Nausea and Vomiting Associated with Chemotherapy or Radiation Therapy in Adults
Explore this paper's citation graph
Summary
The composite outcomes of total control, complete response, and complete response were preferred to the individual outcomes of no emesis and no nausea, and the overall strength of evidence was graded based on the guidance established for the Evidence-based Practice Center Program of AHRQ.
- Type
- article
- Published
- 2010-07-22
- Cited by
- 6
- References
- 46
- OpenAlex
- https://openalex.org/W45920768
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:68073136
Keywords
Aprepitant, Antiemetic, Medicine, Nausea, Vomiting
References
- Methods for Meta-Analysis in Medical Research
- Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
- A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
- Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting
- Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines.
- Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study
- The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
- Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
- Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
- A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
- Current methods of the US Preventive Services Task Force: a review of the process.
- Forest plots: trying to see the wood and the trees
- Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
- Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy
- Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
- Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
- Prognostic factors influencing cisplatin‐induced emesis. Definition and validation of a predictive logistic model
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
- Quantifying heterogeneity in a meta‐analysis
Cited by
- Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.
- Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
- Adding Olanzapine to Three Drugs Anti Emetic Regimen: Is it Time to Jump the Gun?
- ADHERENCE TO ANTIEMESIS GUIDELINES IN A DAY CARE CHEMOTHERAPY UNIT: EXPERIENCE FROM A TERTIARY CARE CENTRE
- Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
- Efficacy of press needle treatment in reducing chemotherapy-induced nausea, vomiting, and retching gastrointestinal cancer patients: A randomized controlled trial
Related papers
- Current Situation of Prophylaxis for Chemotherapy-induced Acute Emesis at Niigata Cancer Center Hospital
- Relieving nausea and vomiting in patients with cancer: a treatment algorithm.
- Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study
- A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center
- Music as an adjunct to antiemetic therapy.
- Pattern of prophylaxis administration for chemotherapy-induced nausea and vomiting: an analysis of city-based health insurance data
- Adherence to Antiemetic Guidelines in Patients with Malignant Glioma: A Quality Improvement Project to Translate Evidence into Practice
- Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer--an inspection of the evidence base informing clinical decision-making.